Sotera Health Company
(NQ:
SHC
)
16.19
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Sotera Health Company
< Previous
1
2
3
4
5
Next >
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
April 06, 2022
Upgrades
Via
Benzinga
Analyst Ratings For Sotera Health
March 21, 2022
Over the past 3 months, 5 analysts have published their opinion on Sotera Health (NASDAQ:SHC) stock. These analysts are typically employed by large Wall Street banks and tasked...
Via
Benzinga
Recap: Sotera Health Q4 Earnings
March 01, 2022
Sotera Health (NASDAQ:SHC) reported its Q4 earnings results on Tuesday, March 1, 2022 at 07:15 AM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
Earnings Scheduled For March 1, 2022
March 01, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...
Via
Benzinga
Sotera Health Earnings Preview
February 28, 2022
Sotera Health (NASDAQ:SHC) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement. Analysts...
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
March 04, 2022
On Friday, 368 stocks hit new 52-week lows. Interesting Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was...
Via
Benzinga
Expert Ratings For Sotera Health
March 03, 2022
Within the last quarter, Sotera Health (NASDAQ:SHC) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2022
March 03, 2022
Upgrades For Douglas Emmett Inc (NYSE:DEI), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. For the fourth quarter, Douglas Emmett had an EPS of $0.48,...
Via
Benzinga
Sotera Health Company (SHC) Q3 2021 Earnings Call Transcript
November 11, 2021
SHC earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Why Sotera Health Stock Is Falling Today
November 10, 2021
Investors weren't happy with the company's full-year guidance.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For March 2, 2022
March 02, 2022
Upgrades Barclays upgraded the previous rating for Equitrans Midstream Corp (NYSE:ETRN) from Underweight to Equal-Weight. Equitrans Midstream earned $0.07 in the fourth...
Via
Benzinga
Sotera Health Company (SHC) Q2 2021 Earnings Call Transcript
August 12, 2021
SHC earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Sotera Health Company (SHC) Q1 2021 Earnings Call Transcript
May 13, 2021
SHC earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
November 10, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:...
Via
Benzinga
Exposures
COVID-19
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
November 08, 2021
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...
Via
Benzinga
Earnings Scheduled For August 12, 2021
August 12, 2021
Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter. • ITeos Therapeutics (NASDAQ:ITOS...
Via
Benzinga
Earnings Scheduled For May 13, 2021
May 13, 2021
Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million. •...
Via
Benzinga
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
May 07, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6) GT Biopharma, Inc. (NASDAQ:...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.